Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) have been given an average recommendation of "Buy" by the five research firms that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued a report on the stock in the last year is $36.60.

A number of research analysts recently issued reports on KNSA shares. Wedbush restated an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a report on Thursday. They issued a "buy" rating and a $40.00 price target for the company.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $18.24, for a total value of $255,360.00. Following the sale, the chief operating officer now owns 88,975 shares of the company's stock, valued at $1,622,904. This trade represents a 13.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 54.57% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Teacher Retirement System of Texas boosted its position in Kiniksa Pharmaceuticals by 7.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after acquiring an additional 719 shares during the last quarter. Martingale Asset Management L P lifted its position in shares of Kiniksa Pharmaceuticals by 1.9% in the fourth quarter. Martingale Asset Management L P now owns 49,360 shares of the company's stock worth $976,000 after purchasing an additional 900 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares during the last quarter. Franklin Resources Inc. grew its position in Kiniksa Pharmaceuticals by 1.7% in the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock valued at $1,798,000 after purchasing an additional 1,100 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in Kiniksa Pharmaceuticals by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after buying an additional 1,374 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Trading Up 4.4 %

Shares of NASDAQ KNSA opened at $22.50 on Thursday. The firm has a market capitalization of $1.63 billion, a PE ratio of -160.70 and a beta of 0.48. The firm's 50-day moving average is $19.90 and its 200-day moving average is $22.23. Kiniksa Pharmaceuticals has a 1 year low of $16.56 and a 1 year high of $28.15.

Remove Ads

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). The company had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company's revenue for the quarter was up 46.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.35 EPS. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.